drugset / Trial / NCT00343252

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252

Phase 3 Completed 712 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.

Timeline

Start
2006-06
Primary completion
2009-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risedronate Small molecule 35 mg Oral
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous